Composition of Total Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of Net Product Sales by Geography

The below table presents our net product sales by geography for the years ended December 31, 2018, 2017, and 2016:



	Year Ended December 31,
	2018				2017				2016
United States	$	91,822	87.9	%	$	107,135	92.2	%	$	125,074	97.3	%
International:
Europe/Canada	11,220		10.7	%	7,727		6.7	%	3,522		2.7	%
Asia Pacific	1,424		1.4	%	1,316		1.1	%	—		—	%
Total International	12,644		12.1	%	9,043		7.8	%	3,522		2.7	%
Product sales, net	$	104,466	100.0	%	$	116,178	100.0	%	$	128,596	100.0	%

Schedule of Net Product Sales by Product Line

The below table presents our net sales by product for the years ended December 31, 2018, 2017, and 2016:



	Year Ended December 31,
	2018				2017				2016
FOLOTYN	$	47,981	45.9	%	$	43,015	37.0	%	$	46,245	36.0	%
EVOMELA	28,292		27.1	%	35,178		30.3	%	16,169		12.6	%
BELEODAQ	12,328		11.8	%	12,353		10.6	%	13,368		10.4	%
ZEVALIN	7,044		6.7	%	11,759		10.1	%	10,730		8.3	%
MARQIBO	5,502		5.3	%	6,573		5.7	%	7,245		5.6	%
FUSILEV*	2,437		2.3	%	7,300		6.3	%	34,839		27.1	%
KHAPZORY	882		0.8	%	—		—	%	—		—	%
Product sales, net**	$	104,466	100.0	%	$	116,178	100.0	%	$	128,596	100.0	%

* Effective December 2018, FUSILEV has been discontinued and we are no longer selling this product. We have since transitioned to marketing KHAPZORY for identical indications as FUSILEV.

** See Note 2(i) for a discussion of our adoption of Topic 606 effective beginning on January 1, 2018.

Summary of Customers Representing 10% or More of Gross Product Sales

The below table presents the customers that represent 10% or more of our gross product sales in 2018, 2017, and 2016:



	Year Ended December 31,
	2018				2017				2016
McKesson Corporation and its affiliates	69,320		36.3	%	76,363		31.1	%	75,952		31.0	%
AmerisourceBergen Corporation, and its affiliates	$	55,576	29.1	%	$	79,362	32.3	%	$	93,951	38.4	%
Cardinal Health, Inc. and its affiliates	42,074		22.0	%	64,634		26.3	%	58,780		24.0	%
All other customers	23,855		12.5	%	25,438		10.3	%	16,087		6.6	%
Gross product sales	$	190,825	100.0	%	$	245,797	100.0	%	$	244,770	100.0	%

The below table presents our license fees and service revenue by source for the years ended December 31, 2018, 2017, and 2016:



	Year Ended December 31,
	2018				2017				2016
Out-license of ZEVALIN: recognition of milestone achievement, upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China (Note 12)	$	2,001	41.1	%	$	1,245	10.2	%	$	1,756	9.8	%
Out-license of FOLOTYN in all countries except the United States, Canada, Europe, and Turkey: royalties (Note 16)	1,860		38.2	%	5,848		48.0	%	927		5.2	%
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory (Note 17(b)(xv))	1,006		20.7	%	5		—	%	6,000		33.6	%
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory (Note17(b)(iii)) and other	—		—	%	50		0.4	%	69		0.4	%
Sales and marketing contracted services (Note 14)	—		—	%	4,747		38.9	%	9,096		51.0	%
Regulatory services provided to licensee	—		—	%	294		2.4	%	—		—	%
License fees and service revenues	$	4,867	100.0	%	$	12,189	100.0	%	$	17,848	100.0	%